en
svPress releases
Press release 2026-03-26
Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased
Regulatory press release 2026-03-26
Xspray Pharma publishes its Annual Report 2025
Regulatory press release 2026-03-24
Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue
Press release 2026-03-11
Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026
Press release 2026-02-26
Xspray Pharma re-submits its FDA application for Dasynoc
Regulatory press release 2026-02-26
Xspray Pharma appoints Blake Leitch as CEO – Per Andersson continues as Chief Scientific Officer (CSO)
Regulatory press release 2026-02-12
Interim Report Fourth Quarter 2025
Regulatory press release 2025-11-05
Interim Report Third Quarter 2025
Press release 2025-10-21
Xspray Pharma: FDA accepts New Drug Application for XS003 (nilotinib) for the treatment of CML – PDUFA date set for June 18, 2026
Regulatory press release 2025-10-10